Compare Motorola Solutions Inc (MSI) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Motorola Solutions Inc vs Recursion Pharmaceuticals Inc — how do they compare? Motorola Solutions Inc trades at $446.82 (market cap $74.20B), while Recursion Pharmaceuticals Inc trades at $4.02 (market cap $2.31B). The key difference: Motorola Solutions Inc is far larger — about 32.1× Recursion Pharmaceuticals Inc's market cap, and Motorola Solutions Inc pays a 1.08% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Motorola Solutions Inc for 100 Days and Recursion Pharmaceuticals Inc for 22 Days on average.
| MSI | RXRX | |
|---|---|---|
Market Cap | $74.20B | $2.31B |
Volume | 720,826 | 40,478,768 |
Sector | Technology | Health |
52-Week High | $491.24 | $6.79 |
52-Week Low | $363.83 | $2.84 |
Typical Hold Time | 100 Days | 22 Days |
Enterprise Value | $83.10B | $1.83B |
Dividend Yield | 1.08% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Motorola Solutions (MSI) trades at $447.12, down 2.02% today, amid a bearish technical signal. The company maintains strong fundamentals with Q2 2026 EPS of $4.41 beating expectations and record backlog of $15.6 billion. Recent acquisitions including D-Fend Solutions for $1.5 billion expand its counter-drone security capabilities, while new contracts with Louisiana and the US Navy demonstrate ongoing demand.
MSI presents a compelling growth story with robust earnings momentum and strategic expansion, though elevated valuation ratios and significant capital expenditures pose risks. Analyst consensus remains bullish with a $525.86 price target, representing 17.6% upside potential from current levels.
RXRX trades at $4.27, down 7.78% today, with a bullish technical signal from moving averages but negative profitability. The company reported a net loss of -$644.76M in 2025, with revenue of $74.26M, and has beaten earnings estimates in two of the last three quarters. Recent news highlights strategic AI partnerships and pipeline expansion, though financial performance remains challenged.
The outlook is mixed: analyst consensus is 40% buy, 60% hold, with no sell ratings, indicating cautious optimism for long-term AI-driven growth. Key risks include persistent cash burn, high valuation multiples, and slow revenue growth. Upside depends on successful drug development and partnership milestones, but near-term profitability remains elusive.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Motorola Solutions Inc
Motorola Solutions, Inc. is a data communications and telecommunications equipment provider. The Company develops data capture, wireless, infrastructure, bar code scanning, two-way radios, and wireless broadband networks. Motorola also produces public safety and government products, voice and data communications products and systems, and wireless LAN securities.
Read more on MSI →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
